Recordati H1 FY26 net income rises 24.8% to € 269.7 million; revenue increases 6.6% to € 1.41 billion

• Recordati first-half 2026 net revenue rose 6.6% to € 1.41 billion; IFRS net income climbed 24.8% to € 269.7 million.
• EBITDA increased 8.8% to € 540.2 million, lifting the margin to 38.3%.
• Rare Diseases revenue grew 17.1% to € 603.9 million, driven by Isturisa revenue up 58.0% to € 178.8 million.
• Free cash flow improved to € 299.4 million; net debt fell to € 1.92 billion, with leverage below 1.9x EBITDA.
• CEO Rob Koremans flagged stepped-up investment for Isturisa’s U.S. expansion; full-year 2026 targets were confirmed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recordati Industria Chimica e Farmaceutica S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 216_170261_2026_oneinfo.pdf), on July 28, 2026, and is solely responsible for the information contained therein.